The gene signature assay, homeobox/interleukin-7 ratio, Breast Cancer Index (Biotheranostics, San Diego, CA, USA), Prosigna assay (NanoString Technologies, Seattle, WA, USA), Oncotype DX assay (Genomic Health, Redwood City, CA, USA), and EndoPredict test (Sividon Diagnostics, Cologne, Germany) have all been employed in efforts to predict early and late recurrence events in patients with breast cancer. This evidence concerns the gene IL7 and breast carcinoma.